美因基因(06667.HK)：延迟刊发2025年中期报告 继续停牌

Group 1 - The core point of the article is that Meigen Gene (06667.HK) announced it will not be able to issue its interim report for the six months ending June 30, 2025, within the required timeframe due to pending matters related to the announcement of its full-year results for 2024 and the issuance of its annual report for 2024 [1] - According to the listing rules, the company is required to send the interim report to its shareholders within three months after the end of the financial period, which is September 30, 2025 [1] - The company's shares remain suspended from trading [1]